MAPT and Alzheimer disease: Furthermore, the majority of research on AD therapeutics has been geared towards targeting AD hallmarks (i.e. amyloid and tau); however, emerging data have unveiled novel pathways in immune cell function, ultimately helping shed light on alternative routes for therapeutic intervention.